Effect and safety of Kanglaite injection combined with chemotherapy in the treatment of advanced colorectal cancer:a systematic review and meta-analysis

Objective:To evaluate the clinical efficacy and safety of Kanglaite injection combined with chemotherapy and chemotherapy alone in the treatment of advanced colorectal cancer.Methods:PubMed,Cochrane library,CNKI,VIP,Wanfang database were systematically searched by inputting keywords to explore the efficacy of Kanglaite injection combined with chemotherapy in the treatment of advanced colorectal cancer.A random-effects model was selected to evaluate the treatment outcomes.The screening of literature,the extraction of data and the assessment of methodology were independently undertaken by two reviewers.Meta analysis was performed using Revman5.3 software and stata15.0 software.Results:A total of 12 RCTs were included,with 792 cases.Compared with chemotherapy alone,Metaanalysis suggested that Kanglaite injection combined with chemotherapy can improve clinical efficiency(RR=1.45,95%CI:1.21-1.74,P<0.0001)and improve patients'quality of life(RR=1.55,95%CI:1.32-1.82,P<0.00001),improve the patient's immune function(CD3+cells:SWD=1.42,95%CI:1.11-1.73;CD4+/CD8+cell ratio:SWD=0.95,95%CI:0.66-1.25;NK cell activity:SWD=3.24,95%CI:2.81-3.66,P<0.00001);Leukopenia rate(RR=0.63,95%CI:0.54-0.74,P<0.0001),incidence of gastrointestinal adverse reactions(RR=0.56,95%CI:0.48-0.66,P<0.00001),incidence of peripheral neurotoxicity(RR=0.79,95%CI:0.65-0.96,P=0.02)were lower than the chemotherapy alone group,the difference was statistically significant.In improving the hand-foot syndrome and oral mucositis after chemotherapy,there was some difference between the Kanglaite injection combined with chemotherapy group and the chemotherapy alone group,but the difference was not significant.Puber bias detection and sensitivity analysis were performed with clinically effective relative risk(RR)as indicators.The results suggested that the publication bias was not obvious.The results of this study are stable.Conclusion:Compared with chemotherapy alone group in the treatment of advanced colorectal cancer,Kanglaite injection combined with chemotherapy can improve the effective rate,quality of life,immune function of patients and reduce the incidence of leukopenia after chemotherapy,gastrointestinal adverse reactions and peripheral neurotoxicity.

Network pharmacology-based elucidation of molecular biological mechanisms of Kanglaite injection for treatment of non-small cell lung cancer

Objective: To investigate the effective compounds, potential targets and molecular mechanism of Kanglaite injection (KLTi) in the treatment of Non-Small Cell Lung Cancer (NSCLC) based on network pharmacology. Methods: The active compounds and targets of KLTi which extracted and isolated from Coix Seed were screened by Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). The related genes of NSCLC were obtained by searching the Human Gene Database (GeneCards) and Online Mendelian Inheritance in Man (OMIM). The candidate targets of KLTi in the treatment of NSCLC were obtained after extracting the intersection network. The "drug-component-target-disease" network was constructed with the help of Cytoscape 3.7.2. The Protein- Protein Interaction networks were constructed on the STRING platform and core network modules were screened. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of candidate genes were performed using Metascape platform, and a "pathway-target- compounds" network was constructed to further screen key genes and active compounds. Results: A total of 11 compounds, 22 candidate targets, 206 GO functions and 12 KEGG pathways were obtained. Conclusion: The active compounds of KLTi in the treatment of NSCLC are stigmasterol, stigmasterol α1 and ergosterol. The key targets are PGR, NCOA2, PTGS2, NR3C2, and PTGS1. The core GO functions included receptor activity and binding, neuronal signal transmission and hormone stimulation;KEGG mainly involves cancer pathways, neuroactive ligand-receptor interactions and calcium signaling pathways. This study reveals the molecular biological mechanism of KLTi in the treatment of NSCLC, which is speculated to be related to neuroendocrine, providing a new basis and therapeutic direction for subsequent clinical application and experimental research.

A Meta-analysis of the efficacy and safety of Kanglaite injection combined with chemotherapy in the treatment of pancreatic cancer

Objective:To investigate the efficacy and safety of Kanglaite injection(KLT)combined with chemotherapy in the treatment of pancreatic cancer.Methods:PubMed,EMBASE,the Cochrane Library,China National Knowledge Infrastructure(CNKI),Wanfang Database,VIP Data,and Chinese Biomedical Database(CBM)were searched to get the studies about KLT plus chemotherapy for pancreatic cancer(from established to May 2019).Data extraction and bias risk assessment were carried out by two authors independently according to the retrieval method.RevMan(version 5.3)were employed for data analysis.Results:A total of 151 literatures were retrieved and 11 literatures were finally included.A total of 614 patients were included,including 308 in the treatment group and 306 in the control group.The results of meta-analysis showed that compared with chemotherapy alone,KLT combined with chemotherapy could improve the effective rate[Porr=0.0009,OR=1.96,95%CI(1.32,2.92)]and disease control rate[Pdcr<0.00001,OR=2.53,95%CI(1.76,3.62)],improve KPS score[P<0.00001,OR=3.59,95%CI(2.00,6.44)]and body mass indexes[P=0.0003,OR=3.45,95%CI(1.78,6.69)],prolong progression free survival(PFS)and overall survival(OS),reduce the rate of myelosuppression[P=0.03,OR=0.54,95%CI(0.30,0.95)],but could not reduce the occurrence of neurotoxicity[P=0.49,OR=0.80,95%CI(0.42,1.51)]and digestive tract reaction[P=0.51,OR=0.83,95%CI(0.48,1.44)].Conclusion:KLT combined with chemotherapy can improve the curative effect of pancreatic cancer,improve the quality of life of patients,prolong the survival of patients,and reduce the incidence of bone marrow suppression.However,due to the limitation of the quality and quantity of included literatures,this conclusion needs to be verified by high-quality study.

Effect of kanglaite injection combined with chemotherapy on tumor factors, angiogenesis and immunoglobulin in patients with lung adenocarcinoma

Objective:To explore the effect of Kanglaite injection combined with chemotherapy on the levels of tumor factors, angiogenesis and immunoglobulin in patients with lung adenocarcinoma.Method: A total of 88 patients with lung adenocarcinoma in our hospital and the Fifth Peoples Hospital of Wuxi from February 2014 to December 2017 were divided randomly into observation group and control group according to the visiting time, 44 cases for each group. The observation group was treated with chemotherapy combined with Kanglaite injection, and the control group was treated with chemotherapy only.Both groups were treated for 6 weeks and then the levels of CEA, CA125, CA199, VEGFA, VEGFB, VEGFC, and IgA, IgM, IgG after treatment in both groups were compared.Result: Before treatment, there were no significant differences in the levels of CEA, CA125 and CA199 between two groups. The level of CEA in the observation group (29.88±7.07) μg/L was lower than that in the control group,and the difference was statistically significant. The levels of CA125 and CA199 after treatment were lower than those before treatment, but with no significant difference. Between the two groups, there was no significant difference of the levels of VEGFA,VEGFB and VEGFC before treatment, the level of VEGFA after treatment in the observation group (80.49±12.29) ng/mL was lower than that in the control group and the difference was statistically significant, and the levels of VEGFB and VEGFC after treatment were also lower than those before treatment, but with no significant difference. The levels of IgA, IgM and IgG before treatment in two groups had no significant difference, The level of IgM after treatment in the observation group (1.52±0.30) g/L was lower than that in the control group, with a statistical difference. The levels of IgA and IgG after treatment were lower than those before treatment, but with no significant difference;No serious adverse reaction was observed after treatment in both groups.Conclusion: Kanglaite injection combined with chemotherapy has a good clinical effect in lung adenocarcinoma, which can effectively inhibit the high expression of tumor markers, reduce angiogenesis, enhance body immunity, and can be recommended for clinical application.

Therapeutic Effects of Kanglaite Injection Combined with Chemotherapy on Advanced Non-small-cell Lung Cancer

The objective of this study was to study the therapeutic effect of Kanglaite injection combined with chemotherapy in the treatment of late-stage nonsmall-cell lung cancer(NSCLC)and also to observe the effect of the combination treatment on immune function.92 patients with advanced stage of NSCLC who admitted to First Hospital of Zibo city hospital from May 2017 to October 2018 were randomly divided into experimentagroup and control group,with 46 cases,respectively.The control group was treated with chemotherapy only while the experimental group was treated with Kanglaite injection combined with chemotherapy which was the basic treatment for patients,and the total treatment effective rate,adverse reaction rate,and immune index of the treatments on two groups were compared.The total treatment effective rate of the experimental group was 80.43%,which was significantly higher than that of the control group,which was 63.04%.The incidence of adverse reactions in the experimental group was 36.96%,which was lower than that of the control group(78.26%).The immune indexes of the experimental group(CD3+,CD4+,IgG,and IgA)were better than that of the control group,respectively.The differences between the two groups were statistically significant(P<0.05).During the chemotherapy of late-stage or advanced NSCLC,the addition use of Kanglaite injection has a significant effect on improving tumor control and reducing the side effects of chemotherapy,and helps to improve the immune function of patients;thus,it is worth promoting.

Effect of kanglaite injection and docetaxel in treating advanced stage esophageal cancer on tumor markers, angiogenesis and immune function in elderly patients

Objective:To investigate the effect of Kanglaite injection combined with docetaxel in advanced esophageal cancer on tumor markers, angiogenesis and immune function in elderly patients.Method:A total of 130 patients with advanced esophageal cancer admitted in our hospital from October 2014 to July 2017were selected and divided into two groups according to the time of admission, 65 cases in each group, set as observation group and control group, all patients were treated with conventional radiotherapy (cisplatin combined with 5-fluorouracil), the observation group was given Kanglaite injection combined with docetaxel on the basis of this, while the control group only was given docetaxel treatment, the treatment period was 6 weeks, tumor markers, VEGF and immune function of both group after treatment were compared.Result: After treatment, the levels of carbohydrate antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9) and carcino-embryonic antigen (CEA) in the observation group were lower than those in the control group, the difference was statistically significant;VEGF level in the observation group after treatment was lower than the control group, the difference was statistically significant;After treatment, the levels of CD3+, CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group, while the levels of CD8+ in the observation group was lower than those in the control group, the difference was statistically significant.Conclusion: Kanglaite injection combined with docetaxel in the treatment of elderly patients with advanced esophageal cancer is better, effectively reducing the level of tumor markers and vascular endothelial growth factor, improve immune function, it isworthy of clinical application.

The efficacy of Kanglaite injection during treatment with tyrosine kinase inhibitor in elderly patients with non-small cell lung cancer

Objective Epidermal growth factor receptor–tyrosine kinase inhibitors(EGFR–TKIs) are widely used in the treatment of EGFR mutation-positive non-small cell lung cancer(NSCLC) patients. The Kanglaite injection(KLT) is a novel broad-spectrum anti-cancer injection produced from traditional Chinese medicinal herbs(coix seed). After its approval in 1995, KLT has become the most popular anti-cancer drug in China. As of this writing, no standard treatment guideline is available for elder patients with NSCLC, and the role of traditional Chinese medicinal herbs, including KLT, combined with TKI treatment remains unknown. This retrospective study evaluated the efficacy and safety of KLT in elderly NSCLC patients during TKI treatment.Methods Thirty elderly patients aged 71-79 years with histopathologically confirmed NSCLC attending the General Hospital of the Shenyang Military Region were enrolled in the study and received EGFR-TKI treatment. All participants received 200 m L KLT injections at the same time on days 1–21. Erlotinib(150 mg) or gefitinib(250 mg) was administered daily from days 1 to 21, and the cycle was repeated every 21 days. The endpoint of the primary study was the disease control rate.Results Thirty elderly patients were enrolled in this study. The objective response rate was 21.3% [95% confidence interval(CI): 8.6% to 35.2%], whereas the disease control rate was 80.4%(95% CI: 71.8% to 97.0%). The grade 3 or 4 adverse effects included leucopenia(13.7%), neutropenia(13.4%), anemia(2.9%), and nausea or vomiting(2.7%). Conclusion The administration of KLT combined with erlotinib or gefitinib showed high efficacy in elderly NSCLC patients. The adverse effects of the drug combination were well tolerated by the patients. KLT combined with TKI treatment might provide a satisfactory therapeutic strategy for elderly NSCLC patients.

调强放疗联合康莱特注射液治疗老年非小细胞肺癌的临床效果及对患者免疫功能的影响观察

目的观察调强放疗联合康莱特注射液治疗老年非小细胞肺癌(NSCLC)的临床效果及对患者免疫功能的影响。方法选取2018年1月至2019年8月于河北省邢台市人民医院就诊的老年NSCLC患者90例,根据治疗方式不同分为对照组和观察组,各45例,患者按完全自愿原则分别加入上述2组。对照组采用调强放疗(5~6周完成),观察组采用调强放疗联合康莱特注射液治疗(静脉滴注连续3周)。记录2组患者治疗前及治疗结束1个月后情况,比较近期疗效、Karnofsky功能状态(KPS)评分、不良反应情况和免疫功能指标水平。结果2组客观缓解率比较差异无统计学意义(P=0.606)。观察组KPS评分提高率高于对照组[64.4%(29/45)比37.8%(17/45)],差异有统计学意义(P=0.020)。观察组白细胞减少发生率低于对照组[13.3%(6/45)比66.7%(15/45)](P=0.045)。治疗后,2组CD_(4)^(+)、CD_(4)^(+)/CD_(8)^(+)比值、自然杀伤细胞水平均高于治疗前且观察组高于对照组,CD_(8)^(+)水平均低于治疗前且观察组低于对照组,差异均有统计学意义(均P<0.05)。结论调强放疗联合中药康莱特注射液治疗能改善老年NSCLC患者的生活质量,降低不良反应发生率,提高免疫功能。

康莱特注射液对乙肝相关性肝癌患者恩替卡韦抗病毒活性作用的影响

目的:探讨康莱特注射液对乙肝相关性肝癌患者恩替卡韦抗病毒活性作用的影响。方法:回顾性分析2020年1月—2022年3月新余钢铁集团有限公司中心医院119例乙肝相关性肝癌患者,根据治疗方法分为两组,分别为联合用药组(n=62)和恩替卡韦组(n=57)。恩替卡韦组给予0.5 mg恩替卡韦胶囊口服治疗,联合用药组在恩替卡韦组的基础上加用康莱特注射液(静脉滴注100 mL)。均治疗6个月。比较两组疗效、凝血功能指标、肝功能指标及不良反应。结果:联合用药组总有效率(87.10%)高于恩替卡韦组(71.93%),差异有统计学意义(P<0.05)。治疗前,两组凝血功能指标比较,差异均无统计学意义(P>0.05);治疗后,两组凝血功能指标均有所改善,且联合用药组的活化部分凝血活酶时间(APTT)、凝血酶时间(TT)、凝血酶原时间(PT)及血浆纤维蛋白原(FIB)均低于恩替卡韦组,差异均有统计学意义(P<0.05)。治疗前,两组肝功能指标比较,差异均无统计学意义(P>0.05);治疗后,两组肝功能指标均有所改善,且治疗后联合用药组的谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素水平(TBIL)、乙肝病毒基因(HBV-DNA)及甲胎蛋白(AFP)均低于恩替卡韦组,而联合用药组的白蛋白(ALB)则高于恩替卡韦组,差异均有统计学意义(P<0.05)。联合用药组的不良反应总发生率(27.42%)高于恩替卡韦组(19.30%),但差异无统计学意义(P>0.05)。结论:康莱特注射液联合恩替卡韦能够有效治疗乙肝相关性肝癌患者,有效抑制HBV-DNA,且其血液功能和肝功能指标均能得到有效改善。

康莱特注射液联合AP化疗方案治疗晚期NSCLC的疗效

目的观察康莱特注射液联合AP化疗方案治疗晚期非小细胞肺癌(NSCLC)的疗效。方法选取2020年1月—2022年12月遵义市中医院收治的晚期NSCLC患者60例作为研究对象,以随机抽签法将患者分为AP化疗组30例和联合化疗组30例。AP化疗组患者采取AP化疗方案治疗,联合化疗组患者在AP化疗组基础上予康莱特注射液治疗,2组均以3周为1个化疗周期,持续治疗4个化疗周期。比较2组近期疗效,治疗前后免疫球蛋白G(IgG)、免疫球蛋白A(IgA)、免疫球蛋白M(IgM)、血清肿瘤标志物[糖类抗原125(CA125)、癌胚抗原(CEA)和神经元特异性烯醇化酶(NSE)]及不良反应。结果联合化疗组客观缓解率为70.00%,高于AP化疗组的43.33%(χ^(2)=4.344,P=0.037)。治疗4个化疗周期后,2组IgG及血清CA125、CEA、NSE水平及AP化疗组IgA、IgM水平均较治疗前降低,但联合化疗组IgG、IgA、IgM水平高于AP化疗组,血清CA125、CEA、NSE水平低于AP化疗组(P<0.05或P<0.01)。联合化疗组血小板减少、血红蛋白减少、恶心呕吐发生率低于AP化疗组(P<0.05)。结论晚期NSCLC患者采取康莱特注射液联合AP化疗方案治疗能够降低免疫耐受及血清肿瘤标志物表达,延缓病情进展,降低不良反应发生率,增强疗效。

康莱特注射液联合化疗在晚期肺癌患者中的应用效果

目的:观察康莱特注射液联合化疗在晚期肺癌患者中的应用效果。方法:选取2019年10月至2022年10月该院收治的86例晚期肺癌患者进行前瞻性研究,按随机数字表法将其分为观察组和对照组各43例。对照组予以化疗,观察组在对照组基础上联合康莱特注射液治疗,比较两组客观缓解率(ORR)、治疗前后肿瘤标志物[神经元特异性烯醇化酶(NSE)、糖类抗原125(CA125)、癌胚抗原(CEA)]水平、肺功能指标[最大通气量(MVV)、用力肺活量(FVC)、第1秒用力呼气容积(FEVl)]水平、视觉模拟评分法(VAS)评分和治疗期间不良反应发生率。结果:观察组ORR为67.44%(29/43),高于对照组的44.19%(19/43),差异有统计学意义(P<0.05);治疗后,观察组NSE、CA125、CEA水平均低于对照组,差异有统计学意义(P<0.05);治疗后,观察组MVV、FVC、FEV1水平均高于对照组,差异有统计学意义(P<0.05);治疗后,两组VAS评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为9.30%(4/43),低于对照组的25.58%(11/43),差异有统计学意义(P<0.05)。结论:康莱特注射液联合化疗应用于晚期肺癌患者可提高ORR和肺功能指标水平,降低肿瘤标志物水平、VAS评分和不良反应发生率,效果优于单纯化疗。

康莱特注射液调控胆固醇代谢以抑制肺腺癌A549细胞的恶性生物学行为

目的:明确康莱特注射液(KLTi)通过调控胆固醇代谢对肺腺癌A549细胞恶性生物学行为的抑制作用。方法:构建A549细胞体外培养模型,设置空白对照组(CON组)、KLTi组、顺铂(DDP)组及KLTi+DDP组,分别给予对应药物干预,采用CCK-8法检测不同分组的药物干预对A549细胞增殖的影响,并确定IC50值用于后续实验;使用细胞划痕实验、平板克隆形成实验、Transwell侵袭实验观察不同分组药物对A549细胞恶性生物学行为的影响;流式细胞术检测不同分组药物对A549细胞晚期凋亡水平的影响;WB法检测各组细胞上皮间质转化(EMT)相关蛋白表达,ELISA法检测促炎因子释放水平。采用比色法检测细胞胆固醇含量水平的组间差异,借助WB法检测胆固醇代谢相关膜通道蛋白ATP结合盒转运蛋白A1(ABCA1)及功能蛋白ATP柠檬酸裂解酶(ACLY)、肽基脯氨酰异构酶B(PPIB)表达水平差异。结果:KLTi及DDP对A549细胞抑制作用具有时间及剂量依赖性(均P<0.05),最终选择2 mg/mL KLTi、3μg/mL DDP作为干预剂量,按分组加药干预48 h后显示,KLTi单用或联合DDP均可抑制A549细胞克隆形成、迁移、侵袭能力且促进其晚期凋亡,KLTi+DDP组的效果更加明显(P<0.05或P<0.01);KLTi单用或联合DDP可通过调控E-cadherin、vimentin、snail蛋白表达从而影响A549细胞EMT进程(P<0.05或P<0.01),同时下调IL-6及IL-8的释放水平(P<0.05或P<0.01)。KLTi单用及联合DDP均可以明显降低A549细胞胆固醇含量(P<0.05或P<0.01),并且对ABCA1、ACLY、PPIB表达具有调控作用,联合组的效果更加明显(P<0.05或P<0.01)。结论:KLTi可能通过调控胆固醇代谢水平及相关通道蛋白抑制肺腺癌A549细胞增殖、迁移、侵袭等恶性生物学行为及EMT进程。

康莱特注射液联合化疗治疗晚期肺癌的疗效及对患者免疫功能、肿瘤标志物的影响

目的 探讨康莱特注射液联合化疗治疗晚期肺癌的疗效及对患者免疫功能、肿瘤标志物的影响。方法依据治疗方法的不同将96例晚期肺癌患者分为对照组和观察组,每组48例,对照组患者给予紫杉醇+顺铂化疗,观察组患者给予紫杉醇+顺铂化疗联合康莱特注射液治疗。比较两组患者的临床疗效、肿瘤标志物[癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、糖类抗原19-9(CA19-9)]水平、外周血T淋巴细胞亚群(CD3^(+)、CD4^(+),计算CD4^(+)/CD8^(+))水平、不良反应发生情况、随访5个月的无病生存率和总生存率。结果 观察组患者的疾病控制率(DCR)为91.67%,高于对照组患者的75.00%,差异有统计学意义(P﹤0.05)。治疗后,两组患者血清CEA、NSE、CA19-9水平均明显低于本组治疗前,且观察组患者血清CEA、NSE、CA19-9水平均明显低于对照组,差异均有统计学意义(P﹤0.01)。治疗后,两组患者CD3^(+)、CD4^(+)水平和CD4^(+)/CD8^(+)均明显低于本组治疗前,但观察组患者CD3^(+)、CD4^(+)水平和CD4^(+)/CD8^(+)均明显高于对照组,差异均有统计学意义(P﹤0.01)。观察组患者的不良反应总发生率为25.00%,低于对照组患者的45.83%(P﹤0.05);随访5个月的无病生存率、总生存率分别为83.33%、95.83%,均高于对照组患者的64.58%、83.33%,差异均有统计学意义(P﹤0.05)。结论 康莱特注射液联合化疗治疗晚期肺癌的疗效显著,可明显改善患者的免疫功能,降低血清肿瘤标志物水平,进一步改善患者的远期预后。

康莱特注射液联合化疗对晚期非小细胞肺癌患者血清肿瘤标志物的影响

目的探讨康莱特注射液联合化疗对晚期非小细胞肺癌患者血清肿瘤标志物的影响。方法将200例晚期非小细胞肺癌患者按照治疗方式的不同分为单独化疗组和联合用药组,每组100例,单独化疗组采用常规化疗方案,联合用药组加用康莱特注射液治疗,两组均治疗2个疗程。比较两组患者的治疗总有效率、免疫功能指标、血清肿瘤标志物、生活质量以及不良反应发生率。结果联合用药组患者的总有效率明显高于单独化疗组,差异有统计学意义(P﹤0.01)。治疗后,联合用药组患者CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)及生命质量测定量表各维度评分均明显高于单独化疗组,血清癌胚抗原、糖类抗原125、糖类抗原19-9水平均明显低于单独化疗组,差异均有统计学意义(P﹤0.01)。联合用药组患者不良反应总发生率低于单独化疗组,差异有统计学意义(P﹤0.05)。结论康莱特注射液联合化疗可有效改善晚期非小细胞肺癌患者的免疫功能,降低血清肿瘤标志物水平和不良反应发生率,提高生活质量,疗效确切。

康莱特注射液联合吉西他滨和替吉奥方案治疗晚期胰腺癌的临床疗效和安全性

目的探究康莱特注射液联合吉西他滨和替吉奥方案治疗晚期胰腺癌的临床疗效和安全性。方法选取2017年6月至2019年5月本院收治的70例晚期胰腺癌患者作为研究对象,按治疗方案不同分为甲组与乙组,各35例。甲组给予吉西他滨+替吉奥治疗,乙组在甲组基础上联合康莱特注射液治疗,比较两组临床疗效、不良反应发生情况及生命质量。结果乙组疾病控制率为71.43%,高于甲组的45.71%,差异有统计学意义(P<0.05)。两组Ⅰ~Ⅱ度、Ⅲ~Ⅳ度的肝功能损伤、消化道反应、血小板抑制、白细胞抑制及红细胞抑制发生率比较差异无统计学意义。治疗前,两组心理健康、情感角色、生理功能、生理影响、躯体疼痛、生命活力、社会功能、总体健康评分比较差异无统计学意义;治疗后,两组心理健康、情感角色、生理功能、生理影响、躯体疼痛、生命活力、社会功能、总体健康评分均高于治疗前,且乙组高于甲组,差异有统计学意义(P<0.05)。结论康莱特注射液联合吉西他滨和替吉奥方案治疗晚期胰腺癌疗效显著,不良反应少,安全性高,可明显改善患者生命质量,值得临床推广应用。

康莱特注射液辅助治疗复发性高级别脑胶质瘤的临床观察

目的:观察康莱特注射液对复发性高级别脑胶质瘤患者免疫功能的影响。方法:选取2018年4月至2022年4月桂林市中医医院收治的复发性高级别脑胶质瘤患者90例作为研究对象,按照简单随机化法随机分为对照组和观察组,每组45例,对照组患者给予替莫唑胺治疗,观察组在对照组基础上加用康莱特注射液,比较2组患者治疗前后血常规指标、免疫功能相关指标、生命质量评分、临床疗效,以及不良反应。结果:对照组脱落2例,观察组脱落1例。治疗后,2组患者白细胞计数(WBC)、中性粒细胞(NE)、血小板计数(PLT)、血红蛋白(Hb)降低,观察组WBC、NE、PLT、Hb高于对照组(均P<0.05);对照组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)降低,CD8^(+)升高(均P<0.05),观察组均无明显变化,观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于对照组(均P<0.05);2组卡诺夫斯凯计分(KPS)、生命质量(QOL)评分升高,观察组KPS、QOL高于对照组(均P<0.05);观察组治疗有效率(90.91%,40/44)高于对照组(74.42%,32/43)(P<0.05)。2组均无严重不良反应发生。结论:复发性高级别脑胶质瘤化疗过程中联合康莱特注射液治疗,可以增加疗效,改善血常规,提高患者免疫功能和生命质量。

康莱特注射液对人胆管癌细胞RBE和HCCC9810生长、凋亡、迁移的影响

目的:探讨康莱特注射液对人胆管癌细胞RBE和HCCC9810生长、凋亡、迁移的影响。方法:使用康莱特注射液处理人胆管癌细胞RBE和HCCC9810,运用CCK-8法检测康莱特注射液对人胆管癌细胞RBE和HCCC9810的增殖情况,流式细胞仪检测两者的凋亡率,Transwell实验检测两者的迁移能力,通过Western Blot检测两者信号通路中关键蛋白Caspase-3、Bcl-2和Bax的表达情况。结果:较之空白对照组,随着康莱特药物作用时间的延长,两者细胞的生长增殖程度逐渐受到抑制(P<0.05),在作用96 h时达到较好抑制状态;Transwell实验结果显示,人胆管癌细胞RBE和HCCC9810经康莱特处理后迁移数量减少(P<0.05);实验组人胆管癌细胞RBE和HCCC9810凋亡率明显增加(P<0.05),两者信号通路中关键蛋白Caspase-3、Bax蛋白表达明显上调(P<0.05),Bcl-2蛋白表达下调(P<0.05)。结论:康莱特注射液可以抑制人胆管癌细胞RBE和HCCC9810的生长和迁移能力,促进其凋亡,机制可能与其能上调凋亡信号通路关键蛋白Caspase-3、Bax和下调Bcl-2蛋白表达有关。

康莱特注射液联合GP化疗方案对NSCLC患者血管内皮生长因子及生存质量的影响

目的探讨康莱特注射液联合GP化疗方案对非小细胞肺癌(NSCLC)患者血管内皮生长因子(VEGF)及生存质量的影响。方法选择赣州市肿瘤医院2019年8月至2021年8月收治的80例NSCLC患者,根据单盲抽法将其分为两组,各40例。对照组采用GP化疗方案,观察组在对照组基础上,采用康莱特注射液治疗,比较两组治疗前、治疗2个月后VEGF水平、生存质量[癌症生命质量核心量表(QLQ-C30)]。结果治疗2个月后,两组VEGF水平低于治疗前,且观察组低于对照组(P<0.05);治疗2个月后角色、躯体、认知、社会、情绪评分均高于治疗前,且观察组各评分高于对照组(P<0.05)。结论康莱特注射液联合GP化疗方案治疗可有效降低NSCLC患者VEGF水平,提高患者生存质量。

康莱特对系膜细胞增殖及端粒酶活性影响的研究

目的:探讨康莱特注射液(KLT)对大鼠系膜细胞(MC)增殖及端粒酶活性的影响。方法:采用活细胞计数法检测不同浓度KLT对MC增殖的影响,采用MTT法检测MC在KLT,IL1(白细胞介素1)分别及共同刺激下的增殖情况,采用端粒重复序列扩增酶联免疫吸附法及聚丙烯酰胺凝胶电泳银染法进行端粒酶活性定量及定性检测并作相关统计学检验。结果:KLT抑制MC增殖,伴随端粒酶活性降低。IL1刺激MC增殖,伴随端粒酶活性升高;两者先后共同作用,抑制MC增殖,抑制端粒酶活性。结论:康莱特对系膜细胞的增殖和端粒酶表达均有抑制作用,并可干预IL1的刺激效应,对防治MC增殖相关的肾小球肾炎可能有应用价值。

康莱特注射液的抗肿瘤作用

观察了康莱特注射液（含薏苡仁中提取的中性油脂）对移植性肿瘤小鼠Ｌｅｗｉｓ肺癌、大鼠Ｗ２５６癌肉瘤、小鼠Ｂ１６黑色素瘤肺转移模型和移植于裸鼠的人体肝癌（ＱＧＹ）的疗效。结果表明，康莱特注射液对上述移植性肿瘤有明显的抑制作用，抑制率分别为７４．１％、５３．２％、７６．４％和８３．８％。